PDCD1 and glioblastoma: Consistent with our mouse data, our analysis of scRNA-seq data obtained from specimens of patients with recurrent GBM treated with neoadjuvant anti–PD-1 and control cohorts revealed that CD69 expression, along with other effector markers, was significantly elevated on TILs from ICI-treated patients compared with the control group.